SCHEMBL1203719

SCHEMBL1203719

O=C(Nc1ccccc1)c1cnc2ccc(CCc3ccccc3)nn12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KIT P10721 2/20 0.45
▸ DDR2 Q16832 2/20 0.45
▸ DDR1 Q08345 1/20 0.45
▸ ALDH1A1 P00352 2/20 0.44
▸ ADRB2 P07550 1/20 0.44
▸ FYN P06241 5/20 0.42
▸ GRK5 P34947 1/20 0.42
▸ MAPT P10636 3/20 0.40
▸ HTT P42858 2/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ LMNA P02545 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ GLA P06280 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ DHODH Q02127 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1202979 0.90 MAPT (0.48) ALDH1A1FYNMAPTHTTLMNA
SCHEMBL1202168 0.85 FYN (0.47) FYNGRK5
SCHEMBL1203092 0.81 EPHX2 (0.46) FYNGRK5MAPTHTTLMNA
SCHEMBL1203528 0.80 SGMS2 (0.47) KITDDR2DDR1MEN1KMT2A
SCHEMBL1203470 0.79 KCNQ3 (0.46) KITDDR2DDR1ALDH1A1KDM4E
SCHEMBL1203606 0.78 FYN (0.59) FYN
SCHEMBL1202745 0.78 MKNK1 (0.56) KITDDR2DDR1ALDH1A1FYN
SCHEMBL1203484 0.76 DDR2 (0.44) KITDDR2DDR1ALDH1A1FYN
SCHEMBL1203163 0.75 FYN (0.46) FYNGRK5MKNK1
SCHEMBL1202432 0.75 KDR (0.52) KITALDH1A1MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110046127-A1 Imidazopyridazines for Use as Protein Kinase Inhibitors CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) 2011-02-24 — — US disclosed
EP-2217601-A1 IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) 2010-08-18 — — EP disclosed
WO-2009060197-A1 IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) 2009-05-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046127-A1 Imidazopyridazines for Use as Protein Kinase Inhibitors PIM1, PIM3, PIM2 KIT 459/4885DDR2 2710/4885DDR1 2158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback